Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06211790CT.gov Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | — | Recruiting | — | — | — |
NCT05485883CT.gov Tislelizumab Plus Lenvatinib in Stage III-IV RCC | — | Unknown | — | — | — |
NCT00747305CT.gov Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery | — | Terminated | — | — | — |
NCT00717587CT.gov Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | — | Unknown | — | — | — |
NCT00626509CT.gov Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer | — | Unknown | — | — | — |
NCT00849186CT.gov Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT01024205CT.gov Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tislelizumab (this asset) | Fudan University | P3 | B · 62 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Tislelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 69 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
| Classic Hodgkin Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tislelizumab in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tislelizumab-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →